RB
66 programs · 63 companies
Programs
66
Companies
63
Trials
50
MOAs
41
PRMT5iEZH2iTNFiDLL3 ADCKRASG12CiSOS1iFcRniVEGFiAuroraAiAnti-Aβ
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Approved | BCL-2 | ||
| RHH-682 | Phase 2 | FXIa | ||
| Ribotuximab | Phase 2 | GPRC5D | ||
| AZN-7403 | Phase 2/3 | FGFR | ||
| AMG-9654 | Phase 2 | GPRC5D | ||
| ALN-6288 | Approved | LAG-3 | ||
| Cevisacituzumab | Preclinical | MALT1 | ||
| Zanufutibatinib | NDA/BLA | CD38 | ||
| Capifutibatinib | Phase 3 | GIP-R | ||
| Capirapivir | Approved | JAK2 | ||
| MRU-1869 | Approved | GPRC5D | ||
| TNG-8610 | NDA/BLA | GIP-R | ||
| VYG-2926 | NDA/BLA | CD19 | ||
| Mirilucimab | NDA/BLA | JAK2 | ||
| CVA-2650 | Phase 2 | IL-23 | ||
| Polasertib | Phase 1 | RET | ||
| Voxafotisoran | Phase 1 | CDK2 | ||
| Gelibrutinib | NDA/BLA | EZH2 | ||
| UCL-IIT-659 | Approved | BCMA | ||
| NCI-IIT-143 | Phase 2 | SGLT2 | ||
| HOR-3601 | Phase 1/2 | FXIa | ||
| MOR-7494 | Phase 1 | SMN2 | ||
| Lisozumab | NDA/BLA | JAK2 | ||
| Olpasacituzumab | Phase 3 | EGFR | ||
| Tixalucimab | Phase 2 | BCL-2 | ||
| Tiracapivasertib | Phase 2 | JAK1 | ||
| Motarasimod | Phase 2 | PCSK9 | ||
| Rimacilimab | Phase 2/3 | MDM2 | ||
| COR-899 | Phase 2/3 | DLL3 | ||
| SNG-5665 | Phase 2/3 | KIF18A | ||
| Nidatinib | Phase 2 | WRN | ||
| Mavucagene | Phase 1/2 | VEGF | ||
| SPI-1775 | Preclinical | PD-1 | ||
| TUR-3071 | NDA/BLA | GIP-R | ||
| AMP-8001 | NDA/BLA | PARP | ||
| Lisocagene | Phase 1 | AuroraA | ||
| Terarapivir | Phase 1 | C5 | ||
| Doxazasiran | Preclinical | KRASG12D | ||
| MOM-2836 | Phase 1/2 | APOC3 | ||
| 255-7731 | Phase 1 | EZH2 | ||
| Lirazumab | Phase 2 | FXIa | ||
| Elracapivasertib | Preclinical | MET | ||
| MIR-6154 | Phase 2 | WEE1 | ||
| BBI-3709 | Phase 1 | AuroraA | ||
| RYT-3886 | Phase 2/3 | Cl18.2 | ||
| Olpasertib | Preclinical | MDM2 | ||
| Ribozanubrutinib | Phase 1 | BET | ||
| Olpasertib | Phase 2 | MALT1 | ||
| YB-4895 | Phase 1/2 | PARP | ||
| Nidaosocimab | Phase 1 | PCSK9 | ||
| 4D-3071 | Approved | BCMA | ||
| Bemazumab | Phase 2/3 | IL-17A | ||
| TOL-8761 | Phase 2 | EGFR | ||
| Kemazanubrutinib | Phase 1/2 | TYK2 | ||
| MOL-8666 | Approved | WEE1 | ||
| Fixabrutinib | Phase 1 | MET | ||
| Ivonesiran | Phase 1/2 | CGRP | ||
| Olpazumab | Phase 1 | CFTR | ||
| Doxacagene | Approved | KRASG12C | ||
| Semafotisoran | Phase 1 | KRASG12C | ||
| TEV-5361 | Preclinical | MALT1 | ||
| HET-7567 | Phase 2 | TYK2 | ||
| Semacapivasertib | Preclinical | CDK4/6 | ||
| A-568 | Approved | CDK2 | ||
| Mavufotisoran | Approved | SMN2 | ||
| Motanaritide | Approved | B7-H3 |
Trials (50)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07098483 | RHH-8550 | Approved | Terminated |
| NCT03048633 | AZN-7403 | Phase 2/3 | Not yet recr... |
| NCT06261980 | Zanufutibatinib | NDA/BLA | Not yet recr... |
| NCT05870469 | Capifutibatinib | Phase 3 | Active |
| NCT07854273 | Capifutibatinib | Phase 3 | Not yet recr... |
| NCT05894996 | Capifutibatinib | Phase 3 | Recruiting |
| NCT03854126 | MRU-1869 | Approved | Not yet recr... |
| NCT05053864 | MRU-1869 | Approved | Active |
| NCT08854320 | MRU-1869 | Approved | Terminated |
| NCT04354265 | TNG-8610 | NDA/BLA | Terminated |
| NCT06078278 | VYG-2926 | NDA/BLA | Recruiting |
| NCT08180470 | Mirilucimab | NDA/BLA | Terminated |
| NCT04706372 | Mirilucimab | NDA/BLA | Not yet recr... |
| NCT03828841 | CVA-2650 | Phase 2 | Not yet recr... |
| NCT03741949 | Voxafotisoran | Phase 1 | Not yet recr... |
| NCT03511490 | UCL-IIT-659 | Approved | Recruiting |
| NCT05373988 | NCI-IIT-143 | Phase 2 | Completed |
| NCT04843050 | HOR-3601 | Phase 1/2 | Terminated |
| NCT06826964 | HOR-3601 | Phase 1/2 | Terminated |
| NCT04209800 | MOR-7494 | Phase 1 | Active |